Safety of efavirenz in the first trimester of pregnancy
- 1 March 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 28, S123-S131
- https://doi.org/10.1097/qad.0000000000000231
Abstract
Introduction:Primate studies and some observational human data have raised concern regarding an association of first-trimester efavirenz exposure with central nervous system congenital anomalies. The objective of this review is to update evidence on efavirenz safety in HIV-infected pregnant women to inform revision of the 2013 WHO guidelines for antiretroviral therapy in low and middle-income countries.Design:A systematic review and meta-analysis.Methods:We searched for studies reporting birth outcomes among women exposed to efavirenz during the first trimester of pregnancy up to 10 January 2014. Relative risks of congenital anomalies comparing women exposed to efavirenz and nonefavirenz-based antiretroviral regimens were pooled using random effects meta-analysis.Results:Twenty-three studies were included in this review, among which 21 reported the birth outcomes of 2026 live births among women exposed to efavirenz during the first trimester of pregnancy. Forty-four congenital anomalies were reported, giving a pooled proportion of 1.63% [95% confidence interval (95% CI) 0.78-2.48], with only one neural tube defect. Twelve studies reported birth outcomes of women exposed to efavirenz or nonefavirenz-containing regimens during the first trimester of pregnancy. Pooled analysis found no differences in overall risks congenital anomalies between these two groups (relative risk 0.78, 95% CI 0.56-1.08). The incidence of neural tube defects was low, 0.05% (95% CI <0.01-0.28), and similar to incidence in the general population.Discussion:This updated analysis found no evidence of an increased risk of overall or central nervous system congenital anomalies associated with first-trimester exposure to efavirenz, similar to previous systematic reviews. This review contributed to the evidence base for the revised 2013 WHO guidelines on antiretroviral therapy, which recommend that efavirenz can be included as part of first-line therapy in adults regardless of sex, and that it can be used throughout pregnancy, including during the first trimester. However, because of the low incidence of central nervous system anomalies in the overall population and relatively small number of exposures in the current literature, continued birth outcomes prospective surveillance is warranted. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & WilkinsKeywords
This publication has 31 references indexed in Scilit:
- Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and PostpartumJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Prevalence of Congenital Anomalies in Infants With In Utero Exposure to AntiretroviralsThe Pediatric Infectious Disease Journal, 2012
- Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral TherapyInfectious Diseases in Obstetrics and Gynecology, 2012
- Pregnancy Outcomes in Women Exposed to Efavirenz and Nevirapine: An Appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'IvoireJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s)HIV Research & Clinical Practice, 2009
- Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conceptionSexually Transmitted Infections, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986